KEGG   DRUG: Telisotuzumab vedotin
Entry
D11344                      Drug                                   
Name
Telisotuzumab vedotin (USAN);
Telisotuzumab vedotin (genetical recombination) (JAN);
Telisotuzumab vedotin-tllv;
Emrelis (TN)
Product
EMRELIS (AbbVie)
Remark
Product: D11344<US>
Efficacy
Antineoplastic, Anti-MET antibody
  Disease
Non-squamous non-small cell lung cancer (c-Met protein overexpression) [DS:H00014]
  Type
Antibody-drug conjugate
Target
MET* [HSA_VAR:4233v2] [HSA:4233] [KO:K05099]
  Pathway
hsa01521  EGFR tyrosine kinase inhibitor resistance
hsa04510  Focal adhesion
hsa04520  Adherens junction
hsa05200  Pathways in cancer
hsa05223  Non-small cell lung cancer
Brite
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   MET family
    MET* [HSA_VAR:4233v2]
     D11344  Telisotuzumab vedotin (USAN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D11344
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D11344
Pharmacogenomic biomarkers [br08341.html]
 Somatic variations in targeted cancer therapies
  D11344
Other DBs
CAS: 1714088-51-3
PubChem: 384585322
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system